Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Sulbactam · 1 trial · 5 indications
The primary efficacy endpoint for the study is 28-day all-cause mortality in the CRABC m-MITT population in Part A.
The primary safety endpoint for the study is nephrotoxicity, as measured by the Risk-Injury-Failure-Loss-End-stage renal disease (RIFLE) criteria, in the MITT population in Part A.
| Arm | Type | Description |
|---|---|---|
| Part A - Group 1 | EXPERIMENTAL | Part A was the pivotal, assessor-blind, randomized, comparative portion of the study in patients with documented ABC hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), ventilated pneumonia (VP), or bacteremia. Part A - Group 1 (experimental): 1.0 g sulbactam/1.0 g durlobactam IV infused over 3 hours every 6 hours (q6h) plus 1.0 g imipenem/1.0 g cilastatin IV infused over 1 hour q6h |
| Part A - Group 2 | ACTIVE_COMPARATOR | Part A - Group 2 (control group): 2.5 mg/kg colistin IV infused over 30 minutes every 12 hours (after an initial loading dose of colistin 2.5 to 5 mg/kg) plus 1.0 g imipenem/1.0 g cilastatin IV infused over 1 hour q6h. |
| Part B - Group 3 | EXPERIMENTAL | Part B (Group 3) was the open-label, supportive portion of the study that included patients known to have HABP, VABP, VP, and/or bacteremia infections associated with ABC organisms resistant to colistin or polymyxin B, who failed a colistin or polymyxin B regimen prior to study entry or were on acute renal replacement therapy, and patients with infections due to colistin- or polymyxin B-resistant ABC with sources of infection other than HABP, VABP, VP, and/or bacteremia. Part B - Group 3: 1.0 g ETX2514/1.0 g sulbactam IV infused over 3 hours q6h plus 1.0 g imipenem/1.0 g cilastatin IV infused over 1 hour q6h. |
| Name | Type | Description |
|---|---|---|
| Sulbactam | DRUG | 1.0 g sulbactam IV infused over 3 hours every 6 hours (q6h). |
| Durlobactam | DRUG | 1.0 g durlobactam IV infused over 3 hours every 6 hours (q6h). Sulbactam-Durlobactam: Treatment for 7 days up to 14 days if clinically indicated. |
| Colistin | DRUG | Treatment for 7 days up to 14 days if clinically indicated. |
| Imipenem/Cilastatin 500 mg/500 mg | DRUG | 1.0 g imipenem/1.0 g cilastatin IV infused over 1 hour q6h. Treatment for 7 days up to 14 days if clinically indicated. |
Inclusion Criteria: PART A 1. A confirmed diagnosis of a serious infection that will require treatment with IV antibiotics; 2. A known infection caused by ABC (bacteremia, HABP, VABP, VP, cUTI or AP, or surgical or post-traumatic wound infections) as either a single pathogen or member of a polymic...
Sulbactam is used for the treatment of infections caused by Acinetobacter Baumannii-calcoaceticus Complex, including hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, bacteremia, and colistin-resistant ABC. It is administered intravenously in combination with durlobactam.
Sulbactam targets beta-lactamase enzymes produced by Acinetobacter Baumannii-calcoaceticus Complex bacteria. By inhibiting these enzymes, it protects the co-administered beta-lactam antibiotic from degradation, enhancing its antibacterial activity against resistant strains.
Sulbactam is being developed by Innoviva, Inc. (NASDAQ: INVA). The company is conducting clinical trials to evaluate the efficacy and safety of intravenous sulbactam in combination with durlobactam for infections caused by Acinetobacter Baumannii-calcoaceticus Complex.
Sulbactam is in Phase 3 clinical development. It is an investigational drug and has not been approved by the FDA. One Phase 3 trial has been completed, with 207 participants enrolled.
Sulbactam is being studied in clinical trial NCT03894046, a Phase 3 study evaluating the efficacy and safety of intravenous sulbactam-ETX2514 in patients with infections caused by Acinetobacter Baumannii-calcoaceticus Complex. The trial has been completed.
Yes, Sulbactam is the same as Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours). The combination is also referred to as Sulbactam/kg-Durlobactam/kg in clinical trial contexts.